Certara Endows Lectureship in Precision Dosing
Certara®, a global biosimulation technology-enabled drug development consultancy, announced that it is endowing a new three-year, full-time position – the Certara Lecturer in Precision Dosing – at the Manchester Pharmacy School, The University of Manchester, England.
Certara®, a global biosimulation technology-enabled drug development consultancy, announced that it is endowing a new three-year, full-time position – the Certara Lecturer in Precision Dosing – at the Manchester Pharmacy School, The University of Manchester, England. This lectureship is intended to advance teaching and research into individual dose optimization modeling, and to demonstrate its application to cancer, pediatric, and biologic therapies.
This new lecturer will work closely with the clinical pharmacy, clinical pharmacology, and quantitative proteomics research groups at The University of Manchester to raise the profile of precision dosing within the university’s precision medicine initiative. This staff member will also lead post-graduate modeling and simulation programs.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
